Ipswich Investment Management Co., Inc. Crispr Therapeutics Ag Transaction History

Ipswich Investment Management Co., Inc.

$410 Million
Q3 2025

A detailed history of Ipswich Investment Management Co., Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Ipswich Investment Management Co., Inc. holds 25,198 shares of CRSP stock, worth $1.93 Million. This represents 0.4% of its overall portfolio holdings.

Number of Shares

25,198

Previous 24,968 0.92%

Holding current value

$1.93 Million

Previous $1.21 Million 34.51%

% of portfolio

0.4%

Previous 0.3%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 08, 2025	BUY	$48.51 - $68.14 $11,157 - $15,672	230 Added 0.92%	25,198 $1.63 Million
Q2 2025 Jul 16, 2025	BUY	$31.27 - $48.64 $13,289 - $20,672	425 Added 1.73%	24,968 $1.21 Million
Q1 2025 Apr 16, 2025	SELL	$34.03 - $53.02 $25,352 - $39,499	-745 Reduced 2.95%	24,543 $835,000
Q4 2024 Feb 03, 2025	BUY	$38.65 - $55.15 $28,987 - $41,362	750 Added 3.06%	25,288 $995,000
Q3 2024 Nov 06, 2024	BUY	$44.62 - $62.75 $7,719 - $10,855	173 Added 0.71%	24,538 $1.15 Million
Q2 2024 Jul 16, 2024	SELL	$51.17 - $68.18 $24,561 - $32,726	-480 Reduced 1.93%	24,365 $1.32 Million
Q1 2024 Apr 19, 2024	BUY	$60.67 - $89.12 $39,435 - $57,928	650 Added 2.69%	24,845 $1.69 Million
Q4 2023 Jan 31, 2024	BUY	$38.62 - $72.18 $23,558 - $44,029	610 Added 2.59%	24,195 $1.51 Million
Q2 2023 Jul 27, 2023	SELL	$43.47 - $67.77 $19,126 - $29,818	-440 Reduced 1.83%	23,585 $1.32 Million
Q1 2023 Apr 24, 2023	SELL	$41.0 - $56.12 $18,245 - $24,973	-445 Reduced 1.82%	24,025 $1.09 Million
Q4 2022 Feb 01, 2023	SELL	$39.19 - $65.67 $27,001 - $45,246	-689 Reduced 2.74%	24,470 $994,000
Q3 2022 Oct 11, 2022	SELL	$61.1 - $83.78 $50,102 - $68,699	-820 Reduced 3.16%	25,159 $1.64 Million
Q2 2022 Jul 26, 2022	SELL	$43.23 - $73.83 $13,012 - $22,222	-301 Reduced 1.15%	25,979 $1.58 Million
Q1 2022 Apr 12, 2022	SELL	$53.19 - $79.24 $24,467 - $36,450	-460 Reduced 1.72%	26,280 $1.65 Million
Q4 2021 Jan 24, 2022	SELL	$70.09 - $111.29 $50,464 - $80,128	-720 Reduced 2.62%	26,740 $2.03 Million
Q3 2021 Oct 07, 2021	BUY	$110.2 - $156.64 $45,182 - $64,222	410 Added 1.52%	27,460 $3.07 Million
Q2 2021 Aug 05, 2021	SELL	$100.84 - $161.89 $3,025 - $4,856	-30 Reduced 0.11%	27,050 $4.38 Million
Q1 2021 Apr 09, 2021	SELL	$110.72 - $210.04 $184,902 - $350,766	-1,670 Reduced 5.81%	27,080 $3.3 Million
Q4 2020 Feb 05, 2021	SELL	$79.67 - $173.23 $213,515 - $464,256	-2,680 Reduced 8.53%	28,750 $4.4 Million
Q3 2020 Oct 06, 2020	SELL	$78.5 - $100.64 $591,497 - $758,322	-7,535 Reduced 19.34%	31,430 $2.63 Million
Q2 2020 Jul 09, 2020	SELL	$38.5 - $76.05 $75,075 - $148,297	-1,950 Reduced 4.77%	38,965 $2.86 Million
Q1 2020 Apr 09, 2020	SELL	$33.68 - $62.53 $78,306 - $145,382	-2,325 Reduced 5.38%	40,915 $1.74 Million
Q4 2019 Jan 08, 2020	SELL	$36.68 - $73.13 $17,789 - $35,468	-485 Reduced 1.11%	43,240 $2.63 Million
Q3 2019 Oct 08, 2019	SELL	$40.99 - $52.56 $13,731 - $17,607	-335 Reduced 0.76%	43,725 $1.79 Million
Q2 2019 Jul 11, 2019	SELL	$35.45 - $48.2 $3,367 - $4,579	-95 Reduced 0.22%	44,060 $2.08 Million
Q1 2019 Apr 12, 2019	SELL	$28.02 - $40.87 $21,295 - $31,061	-760 Reduced 1.69%	44,155 $1.58 Million
Q4 2018 Jan 15, 2019	SELL	$22.73 - $42.34 $33,867 - $63,086	-1,490 Reduced 3.21%	44,915 $1.28 Million
Q3 2018 Oct 09, 2018	SELL	$44.35 - $65.71 $473,436 - $701,454	-10,675 Reduced 18.7%	46,405 $2.06 Million
Q2 2018 Jul 18, 2018	BUY	$42.62 - $73.59 $213 - $367	5 Added 0.01%	57,080 $3.35 Million
Q1 2018 Apr 12, 2018	BUY	$23.52 - $58.17 $207,399 - $512,943	8,818 Added 18.27%	57,075 $2.61 Million
Q4 2017 Jan 16, 2018	BUY	$16.95 - $23.48 $817,956 - $1.13 Million	48,257	48,257 $1.13 Million

Others Institutions Holding CRSP

# of Institutions

533

Shares Held

68.7M

Call Options Held

3.67M

Put Options Held

2.25M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $5.99B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ipswich Investment Management Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ipswich Investment Management Co., Inc. with notifications on news.

Account

Ipswich Investment Management Co., Inc. Crispr Therapeutics Ag Transaction History